Mycobacterial antigen for delayed-type hypersensitivity testing
Tuberculin purified protein derivative
Adult dose
Dose: Mantoux: 0.1mL (2 TU) intradermal forearm; read induration at 48-72h
Route: Intradermal
Frequency: per indication
Clinical pearls
- TB screening (latent infection); LTBI screen per NICE NG33
- IGRA preferred in BCG-vaccinated individuals
Contraindications
- Active TB
- Severe febrile illness
- Hypersensitivity
Side effects
- Local reaction
- Vesiculation
- Hypersensitivity (rare)
Interactions
- Live vaccines (within 4 weeks)
- Recent corticosteroids (false negative)
Reference: BNF; UKHSA Green Book Ch.32; NICE NG33; https://bnf.nice.org.uk/drugs/tuberculin-purified-protein-derivative/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Rate-Pressure Product (RPP) · Haemodynamics
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- Fontan Circulation Risk Assessment · Congenital Heart Disease
- Severe Drug Reaction Severity Score (RegiSCAR) · Drug Reactions
- Insulin TDD Estimator · Diabetes
- AUSDRISK — Australian Type 2 Diabetes Risk Tool · Diabetes Risk
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023